India M&A Uptick: Have The Planets Aligned?

The recent uptick in M&A on the Indian pharmaceutical market points to tempered valuations and the potential for further consolidation. Scrip spoke to a cross-section of experts including investment bankers on deal street expectations, foreign interest in M&A and whether family-led Indian firms may now be more open to sell-offs.

Big fish
INDIA HAS SEEN A SPURT IN M&A AMID TEMPERED VALUATIONS

Two pharma M&A deals on the trot in November have highlighted the softened valuation expectations by sellers on the fragmented Indian market, potentially setting the tone for more consolidation.

On Nov. 3, Torrent Pharmaceuticals Ltd., which is believed to have missed out on a string of prominent acquisitions...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.